The Chorionic Gonadotropin Market is expected to register a CAGR of 7.4% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Type (Human Chorionic Gonadotropin (HCG), Animal Chorionic Gonadotropin); and End User (Research institutions, Pharmaceutical Companies, Others). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.
Purpose of the ReportThe report Chorionic Gonadotropin Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Chorionic Gonadotropin Market Segmentation
Type- Human Chorionic Gonadotropin
- Animal Chorionic Gonadotropin
- Research institutions
- Pharmaceutical Companies
Strategic Insights
Chorionic Gonadotropin Market Growth Drivers- Rising Incidence of Infertility and Hormonal Imbalances: The increasing global prevalence of infertility and hormonal imbalances, particularly among women, is a significant growth driver for the chorionic gonadotropin (hCG) market. Infertility rates are rising globally due to factors such as delayed pregnancies, lifestyle changes, and stress. Hormonal imbalances such as polycystic ovary syndrome (PCOS) and thyroid disorders are also contributing to the growing demand for fertility treatments. As hCG plays a crucial role in stimulating ovulation and improving sperm production, it is a primary treatment option for individuals undergoing assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intrauterine insemination (IUI). With the growing prevalence of these conditions, the demand for hCG is expected to rise, leading to a significant expansion in market size and share. Additionally, the increasing focus on reproductive health and the availability of specialized clinics that offer fertility treatments are expected to boost the adoption of hCG products. The growing awareness and acceptance of ART procedures globally are also expected to increase market demand for hCG. As more couples seek infertility treatments, particularly in regions such as North America, Europe, and Asia, the chorionic gonadotropin market will experience sustained growth.
- Advancements in Fertility Treatments: Technological advancements in fertility treatments are fueling the growth of the chorionic gonadotropin (hCG) market. With the increasing success rates of assisted reproductive technologies (ART) like IVF and IUI, the demand for hCG as a critical component in these procedures is expected to rise significantly. hCG is used to induce ovulation in women and enhance sperm production in men, making it an essential part of many ART regimens. The continued research and development in fertility treatments, including genetic screening, cryopreservation, and hormone-based therapies, are contributing to the growing demand for hCG. Additionally, improvements in IVF protocols that require the use of hCG to trigger egg maturation and increase fertilization success are further driving the market’s growth. Fertility clinics and reproductive health specialists are adopting newer techniques, making ART more accessible and effective, which directly benefits the hCG market. As a result, the market for hCG is witnessing an upward trajectory due to the expanding use of hCG in ART procedures. The growing prevalence of female infertility, coupled with the technological advancements that enhance the success rate of these treatments, is expected to further increase the demand for hCG products worldwide.
- Expanding Male Infertility Treatment Market: The increasing recognition and treatment of male infertility is another key growth driver for the chorionic gonadotropin (hCG) market. Previously, male infertility has often been overlooked, but as awareness of the condition grows, more men are seeking medical treatment. hCG is widely used in male infertility treatments to stimulate testosterone production and enhance sperm production, making it an essential component of many male fertility regimens. Male infertility treatments often involve the use of hCG alongside other medications to improve semen quality and fertility outcomes. With growing awareness of male reproductive health, more men are opting for treatments, especially as they seek solutions to low testosterone levels and diminished sperm count. This trend is expected to lead to a greater demand for hCG-based fertility treatments. Furthermore, the growing popularity of testosterone replacement therapies, often used in combination with hCG to restore normal testosterone levels and improve sperm production, is contributing to the market's growth. As fertility clinics and healthcare providers increasingly focus on male fertility, the chorionic gonadotropin market is poised for further expansion. Male infertility treatments are expected to gain prominence, thus driving the demand for hCG products in the coming years.
- Integration of Artificial Intelligence in Fertility Treatment: The integration of Artificial Intelligence (AI) in fertility treatments is a significant trend driving the growth of the chorionic gonadotropin (hCG) market. AI technologies are revolutionizing healthcare, and fertility treatments are no exception. AI is increasingly being used to analyze patient data, predict ovulation cycles, and optimize medication dosages, including the administration of hCG. Fertility clinics are adopting AI-driven tools to enhance the precision of treatments, improving success rates in procedures like in vitro fertilization (IVF) and intrauterine insemination (IUI). AI can help fertility specialists personalize treatment protocols, including the use of hCG, based on real-time data, allowing for more accurate timing of ovulation and improved chances of conception. As AI continues to evolve, it is expected to make fertility treatments more efficient and effective, further fueling the demand for hCG. AI-powered solutions also help in monitoring the progress of treatment, providing insights into the best time for hCG administration, and improving the overall patient experience. With increasing adoption of AI technology in fertility clinics globally, the hCG market is poised for growth, as AI plays a critical role in optimizing treatments, reducing costs, and increasing patient satisfaction.
- Government Initiatives and Subsidies for Fertility Treatments: Government support and subsidies for fertility treatments are emerging as a significant trend in the chorionic gonadotropin (hCG) market. Many governments worldwide are recognizing the growing need for fertility treatments as infertility rates rise. In response, some governments are offering financial assistance, subsidies, or insurance coverage for ART procedures, including IVF, IUI, and other fertility treatments where hCG is used. This support not only makes fertility treatments more accessible but also encourages individuals and couples to seek professional help for infertility, thereby increasing the demand for hCG. For instance, countries like Canada, Australia, and parts of Europe have introduced policies to cover fertility treatments for their citizens. In regions like Asia-Pacific, where fertility treatments were once limited to a small section of the population, government-backed initiatives are now enabling broader access. These initiatives will lead to higher treatment volumes, particularly in under-served regions, driving the demand for hCG in assisted reproductive technologies. Government intervention in the fertility sector is expected to continue growing, creating a favorable environment for the chorionic gonadotropin market to expand and serve a wider demographic.
- Increased Focus on Personalized Fertility Treatments: Personalized fertility treatments are another major trend in the chorionic gonadotropin (hCG) market. Advances in genetics and reproductive health have enabled fertility specialists to offer more customized treatment plans to patients, optimizing their chances of success. The use of hCG as part of these personalized treatments is expected to grow, as it plays a crucial role in stimulating ovulation and improving sperm production. Personalized treatment protocols involve careful monitoring of hormone levels, tailoring medication dosages, and using a combination of therapies to address individual needs. The increasing use of genetic screening to assess patients' fertility potential and tailor treatment options has led to better success rates in fertility treatments, further driving demand for hCG. With the rise of precision medicine in the fertility space, more couples are seeking treatments that are customized to their specific conditions, contributing to the market’s expansion. This trend is expected to accelerate as healthcare providers increasingly offer personalized services that use hCG to improve fertility outcomes. The ability to tailor treatments to individual patients’ needs will continue to play a major role in the growing adoption of hCG in fertility treatments.
- Growing E-commerce and Online Pharmacies for hCG Sales: The rise of e-commerce and online pharmacies is a valuable growth opportunity for the chorionic gonadotropin (hCG) market. With the global trend toward online shopping, patients are increasingly purchasing fertility medications, including hCG, through online platforms. This shift in purchasing behavior has created a new avenue for the distribution of hCG products, offering convenience and accessibility to a broader customer base. Online pharmacies allow patients to order fertility medications discreetly and conveniently, especially for those who may be uncomfortable buying these products in person. The convenience of doorstep delivery and easy access to medical advice makes online platforms a preferred choice for many. As e-commerce continues to grow, online pharmacies are expected to play a crucial role in expanding the reach of hCG-based treatments. This growth in online sales also opens doors to previously underserved regions where access to physical fertility clinics or pharmacies may be limited. As digital healthcare solutions become more prominent, online pharmacies are set to become a key channel for the delivery of fertility medications. This trend will contribute to increased market penetration, boosting the growth of the hCG market globally. Moreover, e-commerce platforms enable manufacturers to reach a wider audience, reducing distribution costs and enhancing product availability in various regions.
- Rising Demand for Fertility Preservation Among Women: Rising demand for fertility preservation is a significant growth opportunity for the chorionic gonadotropin (hCG) market. As more women delay childbirth due to personal, social, or career-related reasons, there is an increasing demand for fertility preservation options. This has led to a rise in the popularity of egg freezing and other assisted reproductive technologies (ART), where hCG plays a key role in inducing ovulation before egg retrieval. Fertility preservation allows women to store their eggs at a younger age, preserving their fertility for future use. The rising societal trend of later family planning, combined with increased awareness of reproductive health, is driving demand for such services. As women in their 30s and 40s opt for egg freezing, hCG becomes essential for the stimulation of ovarian follicles and the maturation of eggs. This trend toward fertility preservation is expected to continue growing, creating a substantial demand for hCG in the coming years. Fertility clinics are increasingly offering egg freezing services as part of their ART offerings, and as this market grows, so too will the need for hCG. This provides a unique opportunity for hCG manufacturers to expand their product offerings and capture a larger share of the reproductive healthcare market. As fertility preservation becomes more mainstream, the demand for hCG in ART procedures will continue to rise.
- Development of Novel hCG-based Products and Formulations: An exciting growth opportunity for the chorionic gonadotropin (hCG) market lies in the development of novel hCG-based products and formulations. Pharmaceutical companies are continuously innovating to improve the efficacy, safety, and patient experience of fertility treatments. Newer formulations of hCG, such as long-acting or sustained-release versions, are gaining traction as they reduce the frequency of injections and enhance patient compliance. These innovations aim to make hCG treatments more convenient and effective for patients undergoing fertility treatments. Additionally, combining hCG with other fertility drugs is another area of development. Such combination therapies can offer a more holistic approach to fertility treatment, providing patients with more options tailored to their needs. The introduction of novel hCG products also addresses some of the limitations of existing formulations, such as the need for frequent injections or the potential for side effects. With advancements in drug delivery systems and formulation technology, hCG products are expected to become more patient-friendly, boosting their adoption in fertility clinics. These product innovations are expected to drive market growth as they enhance treatment outcomes and improve overall patient satisfaction. By developing more effective and convenient hCG-based products, manufacturers can cater to the evolving needs of patients and further expand their market presence.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Chorionic Gonadotropin Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Chorionic Gonadotropin Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?

Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities

Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
This text is related
to segments covered.

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Chorionic Gonadotropin Market is estimated to witness a CAGR of 7.4% from 2025 to 2031.
The major factors driving the Chorionic Gonadotropin Market are Rising Incidence of Infertility and Hormonal Imbalances, Advancements in Fertility Treatments, Expanding Male Infertility Treatment Market.
Future trends in the Chorionic Gonadotropin Market are Integration of Artificial Intelligence in Fertility Treatment, Increased Focus on Personalized Fertility Treatments, Government Initiatives and Subsidies for Fertility Treatments.
Some of the players operating in the market are Scrippslabs, Leebio, Kamiya Biomedical Company, Merck & Co, Inc., Fresenius Kabi AG, Ferring B. V., Cigna, Sanzyme, Lupin AB, Prospec-Tany Technogene Ltd.
The report can be delivered in PDF/PPT format; we can also share an excel datasheet based on the request.
Some customization options available based on the request are an additional 3–5 company profiles and a country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation# as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Chorionic Gonadotropin Market - By Type
1.3.2 Chorionic Gonadotropin Market - By End User
1.3.3 Chorionic Gonadotropin Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CHORIONIC GONADOTROPIN MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CHORIONIC GONADOTROPIN MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CHORIONIC GONADOTROPIN MARKET - GLOBAL MARKET ANALYSIS
6.1. CHORIONIC GONADOTROPIN - GLOBAL MARKET OVERVIEW
6.2. CHORIONIC GONADOTROPIN - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CHORIONIC GONADOTROPIN MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. HUMAN CHORIONIC GONADOTROPIN (HCG)
7.3.1. Overview
7.3.2. Human Chorionic Gonadotropin (HCG) Market Forecast and Analysis
7.4. ANIMAL CHORIONIC GONADOTROPIN
7.4.1. Overview
7.4.2. Animal Chorionic Gonadotropin Market Forecast and Analysis
8. CHORIONIC GONADOTROPIN MARKET - REVENUE AND FORECASTS TO 2028 - END USER
8.1. OVERVIEW
8.2. END USER MARKET FORECASTS AND ANALYSIS
8.3. RESEARCH INSTITUTIONS
8.3.1. Overview
8.3.2. Research institutions Market Forecast and Analysis
8.4. PHARMACEUTICAL COMPANIES
8.4.1. Overview
8.4.2. Pharmaceutical Companies Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. CHORIONIC GONADOTROPIN MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Chorionic Gonadotropin Market Overview
9.1.2 North America Chorionic Gonadotropin Market Forecasts and Analysis
9.1.3 North America Chorionic Gonadotropin Market Forecasts and Analysis - By Type
9.1.4 North America Chorionic Gonadotropin Market Forecasts and Analysis - By End User
9.1.5 North America Chorionic Gonadotropin Market Forecasts and Analysis - By Countries
9.1.5.1 United States Chorionic Gonadotropin Market
9.1.5.1.1 United States Chorionic Gonadotropin Market by Type
9.1.5.1.2 United States Chorionic Gonadotropin Market by End User
9.1.5.2 Canada Chorionic Gonadotropin Market
9.1.5.2.1 Canada Chorionic Gonadotropin Market by Type
9.1.5.2.2 Canada Chorionic Gonadotropin Market by End User
9.1.5.3 Mexico Chorionic Gonadotropin Market
9.1.5.3.1 Mexico Chorionic Gonadotropin Market by Type
9.1.5.3.2 Mexico Chorionic Gonadotropin Market by End User
9.2. EUROPE
9.2.1 Europe Chorionic Gonadotropin Market Overview
9.2.2 Europe Chorionic Gonadotropin Market Forecasts and Analysis
9.2.3 Europe Chorionic Gonadotropin Market Forecasts and Analysis - By Type
9.2.4 Europe Chorionic Gonadotropin Market Forecasts and Analysis - By End User
9.2.5 Europe Chorionic Gonadotropin Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Chorionic Gonadotropin Market
9.2.5.1.1 Germany Chorionic Gonadotropin Market by Type
9.2.5.1.2 Germany Chorionic Gonadotropin Market by End User
9.2.5.2 France Chorionic Gonadotropin Market
9.2.5.2.1 France Chorionic Gonadotropin Market by Type
9.2.5.2.2 France Chorionic Gonadotropin Market by End User
9.2.5.3 Italy Chorionic Gonadotropin Market
9.2.5.3.1 Italy Chorionic Gonadotropin Market by Type
9.2.5.3.2 Italy Chorionic Gonadotropin Market by End User
9.2.5.4 Spain Chorionic Gonadotropin Market
9.2.5.4.1 Spain Chorionic Gonadotropin Market by Type
9.2.5.4.2 Spain Chorionic Gonadotropin Market by End User
9.2.5.5 United Kingdom Chorionic Gonadotropin Market
9.2.5.5.1 United Kingdom Chorionic Gonadotropin Market by Type
9.2.5.5.2 United Kingdom Chorionic Gonadotropin Market by End User
9.2.5.6 Rest of Europe Chorionic Gonadotropin Market
9.2.5.6.1 Rest of Europe Chorionic Gonadotropin Market by Type
9.2.5.6.2 Rest of Europe Chorionic Gonadotropin Market by End User
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Chorionic Gonadotropin Market Overview
9.3.2 Asia-Pacific Chorionic Gonadotropin Market Forecasts and Analysis
9.3.3 Asia-Pacific Chorionic Gonadotropin Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Chorionic Gonadotropin Market Forecasts and Analysis - By End User
9.3.5 Asia-Pacific Chorionic Gonadotropin Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Chorionic Gonadotropin Market
9.3.5.1.1 Australia Chorionic Gonadotropin Market by Type
9.3.5.1.2 Australia Chorionic Gonadotropin Market by End User
9.3.5.2 China Chorionic Gonadotropin Market
9.3.5.2.1 China Chorionic Gonadotropin Market by Type
9.3.5.2.2 China Chorionic Gonadotropin Market by End User
9.3.5.3 India Chorionic Gonadotropin Market
9.3.5.3.1 India Chorionic Gonadotropin Market by Type
9.3.5.3.2 India Chorionic Gonadotropin Market by End User
9.3.5.4 Japan Chorionic Gonadotropin Market
9.3.5.4.1 Japan Chorionic Gonadotropin Market by Type
9.3.5.4.2 Japan Chorionic Gonadotropin Market by End User
9.3.5.5 South Korea Chorionic Gonadotropin Market
9.3.5.5.1 South Korea Chorionic Gonadotropin Market by Type
9.3.5.5.2 South Korea Chorionic Gonadotropin Market by End User
9.3.5.6 Rest of Asia-Pacific Chorionic Gonadotropin Market
9.3.5.6.1 Rest of Asia-Pacific Chorionic Gonadotropin Market by Type
9.3.5.6.2 Rest of Asia-Pacific Chorionic Gonadotropin Market by End User
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Chorionic Gonadotropin Market Overview
9.4.2 Middle East and Africa Chorionic Gonadotropin Market Forecasts and Analysis
9.4.3 Middle East and Africa Chorionic Gonadotropin Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Chorionic Gonadotropin Market Forecasts and Analysis - By End User
9.4.5 Middle East and Africa Chorionic Gonadotropin Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Chorionic Gonadotropin Market
9.4.5.1.1 South Africa Chorionic Gonadotropin Market by Type
9.4.5.1.2 South Africa Chorionic Gonadotropin Market by End User
9.4.5.2 Saudi Arabia Chorionic Gonadotropin Market
9.4.5.2.1 Saudi Arabia Chorionic Gonadotropin Market by Type
9.4.5.2.2 Saudi Arabia Chorionic Gonadotropin Market by End User
9.4.5.3 U.A.E Chorionic Gonadotropin Market
9.4.5.3.1 U.A.E Chorionic Gonadotropin Market by Type
9.4.5.3.2 U.A.E Chorionic Gonadotropin Market by End User
9.4.5.4 Rest of Middle East and Africa Chorionic Gonadotropin Market
9.4.5.4.1 Rest of Middle East and Africa Chorionic Gonadotropin Market by Type
9.4.5.4.2 Rest of Middle East and Africa Chorionic Gonadotropin Market by End User
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Chorionic Gonadotropin Market Overview
9.5.2 South and Central America Chorionic Gonadotropin Market Forecasts and Analysis
9.5.3 South and Central America Chorionic Gonadotropin Market Forecasts and Analysis - By Type
9.5.4 South and Central America Chorionic Gonadotropin Market Forecasts and Analysis - By End User
9.5.5 South and Central America Chorionic Gonadotropin Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Chorionic Gonadotropin Market
9.5.5.1.1 Brazil Chorionic Gonadotropin Market by Type
9.5.5.1.2 Brazil Chorionic Gonadotropin Market by End User
9.5.5.2 Argentina Chorionic Gonadotropin Market
9.5.5.2.1 Argentina Chorionic Gonadotropin Market by Type
9.5.5.2.2 Argentina Chorionic Gonadotropin Market by End User
9.5.5.3 Rest of South and Central America Chorionic Gonadotropin Market
9.5.5.3.1 Rest of South and Central America Chorionic Gonadotropin Market by Type
9.5.5.3.2 Rest of South and Central America Chorionic Gonadotropin Market by End User
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL CHORIONIC GONADOTROPIN MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. CHORIONIC GONADOTROPIN MARKET, KEY COMPANY PROFILES
12.1. SCRIPPSLABS
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. LEEBIO
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. KAMIYA BIOMEDICAL COMPANY
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. MERCK AND CO, INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. FRESENIUS KABI AG
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. FERRING B. V.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. CIGNA
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SUN PHARMACEUTICAL INDUSTRIES LTD
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. SANZYME
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. LUPIN AB
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
12.11. PROSPEC-TANY TECHNOGENE LTD
12.11.1. Key Facts
12.11.2. Business Description
12.11.3. Products and Services
12.11.4. Financial Overview
12.11.5. SWOT Analysis
12.11.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Scrippslabs
2. Leebio
3. Kamiya Biomedical Company
4. Merck & Co, Inc.
5. Fresenius Kabi AG
6. Ferring B. V.
7. Cigna
8. Sanzyme
9. Lupin AB
10. Prospec-Tany Technogene Ltd
11. Midas Pharma GmbH
12. Trumac Healthcares
13. Ceva
14. Nexus Lifecare
15. LGM Pharma
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.